ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve in humans. Spike protein mutations increase transmission and potentially evade antibodies raised against the original sequence used in current vaccines. Our evaluation of serum neutralizing activity in both persons soon after SARS-CoV-2 infection (in April 2020 or earlier) or vaccination without prior infection confirmed that common spike mutations can reduce antibody antiviral activity. However, when the persons with prior infection were subsequently vaccinated, their antibodies attained an apparent biologic ceiling of neutralizing potency against all tested variants, equivalent to the original spike sequence. These findings indicate that additional antigenic exposure further improves antibody efficacy against variants.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccines, vaccine efficacy, Humoral immunity, spike variants, 【초록키워드】 severe acute respiratory syndrome coronavirus 2, Efficacy, coronavirus, vaccination, Mutation, spike, antibody, SARS-COV-2 infection, Infection, Transmission, antiviral activity, severe acute respiratory syndrome Coronavirus, variants, Spike protein, Protein, serum, Neutralizing activity, spike mutation, humans, Neutralizing, respiratory, biologic, acute respiratory syndrome, acute respiratory syndrome coronavirus, antigenic, sequence, potency, IMPROVE, tested, raised, evade, reduce, 【제목키워드】 Combined, Produce,